Media stories about Five Prime Therapeutics (NASDAQ:FPRX) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.8225395423773 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s analysis:
- $9.86 Million in Sales Expected for Five Prime Therapeutics Inc (FPRX) This Quarter (americanbankingnews.com)
- Five Prime Therapeutics Inc (FPRX) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
- Eye-Catching Shares – Five Prime Therapeutics, Inc., (NASDAQ: FPRX) – Stock Watch (stocksnewstimes.com)
- Five Prime Therapeutics, Inc. (NASDAQ:FPRX) – Hot Stock’s Watch List – Nasdaq Journal (press release) (nasdaqjournal.com)
- Today’s Hot Mover – Five Prime Therapeutics, Inc. (NASDAQ: FPRX) – The Investor Guide (wallstreetnews24.com)
FPRX has been the subject of several research reports. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price objective for the company in a research note on Monday, October 16th. Royal Bank of Canada boosted their price objective on Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, November 6th. BMO Capital Markets boosted their price objective on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 7th. Jefferies Group reiterated a “buy” rating and set a $52.00 price objective on shares of Five Prime Therapeutics in a research note on Tuesday, September 12th. Finally, ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $64.00.
Five Prime Therapeutics (NASDAQ:FPRX) traded down $0.84 during mid-day trading on Friday, hitting $20.05. The stock had a trading volume of 2,408,736 shares, compared to its average volume of 479,719. Five Prime Therapeutics has a 1-year low of $19.73 and a 1-year high of $53.89.
Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.19). Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The business had revenue of $8.33 million during the quarter, compared to analyst estimates of $16.16 million. During the same quarter in the prior year, the company posted ($0.72) earnings per share. The company’s revenue was up 24.7% on a year-over-year basis. sell-side analysts predict that Five Prime Therapeutics will post -5.56 EPS for the current fiscal year.
In other Five Prime Therapeutics news, Director William R. Ringo sold 1,800 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $40.26, for a total transaction of $72,468.00. Following the transaction, the director now directly owns 1,200 shares in the company, valued at $48,312. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William R. Ringo sold 600 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the transaction, the director now owns 600 shares in the company, valued at $27,198. The disclosure for this sale can be found here. Insiders sold 4,400 shares of company stock worth $175,666 over the last quarter. 6.50% of the stock is currently owned by insiders.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.